Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

INTRODUCTION: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a mechanism of trametinib resistance in KRAS-mutant NSCLC, and combination therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbour, Kathryn C., Manchado, Eusebio, Bott, Matthew J., Ahn, Linda, Tobi, Yosef, Ni, Andy Ai, Yu, Helena A., Shannon, Alyssa, Ladanyi, Marc, Perron, Victoria, Ginsberg, Michelle S., Johnson, Amanda, Holodny, Andrei, Kris, Mark G., Rudin, Charles M., Lito, Piro, Rosen, Neal, Lowe, Scott, Riely, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693267/
https://www.ncbi.nlm.nih.gov/pubmed/34984405
http://dx.doi.org/10.1016/j.jtocrr.2021.100256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693267/
https://www.ncbi.nlm.nih.gov/pubmed/34984405
http://dx.doi.org/10.1016/j.jtocrr.2021.100256

Ejemplares similares